Channel Medsystems Announces Appointment of Three Key Executives to Management Team and Expanded Launch of Cerene® Cryotherapy for Heavy Menstrual Bleeding
Retrieved on:
Thursday, March 31, 2022
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Fitness & Nutrition, Clinical Trials, Other Health, Adoption, GRAIL, Company, Journal, Marketing, LinkedIn, Dickson Manufacturing Company, Patient, Endometrium, Hospital, Woman, Takeda, Nital, Pain, Channel, Gynaecology, Cryotherapy, CA, Becton, Physician, Awareness, Accounting, FDA, Customer, PMA, Risk management, Pharmaceutical industry, Birth control, Omri Ceren, CERENE CRYOTHERAPY, CHANNEL MEDSYSTEMS
These appointments follow the success of the companys early commercial launch of its Cerene Cryotherapy treatment for heavy menstrual bleeding in September 2021.
Key Points:
- These appointments follow the success of the companys early commercial launch of its Cerene Cryotherapy treatment for heavy menstrual bleeding in September 2021.
- These executives were brought on to continue the momentum of the companys initial market introduction of Cerene, a novel endometrial ablation option that uniquely facilitates the in-office treatment of heavy menstrual bleeding.
- Cerene was first introduced into the market by Channel Medsystems supported by a major financing closed in August 2021.
- Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia.